STRATA Skin Sciences (NASDAQ: SSKN) has affirmed its strong patent portfolio position for combination therapies using its XTRAC excimer laser with JAK inhibitors, systemic and biologic drugs. The company holds three key patents that protect the combined use of their technology with various therapeutic agents for treating dermatologic conditions.
The company is working with CMS to implement expanded CPT codes that would cover all inflammatory and autoimmune skin conditions, potentially tripling their addressable market by January 2026. This expansion includes conditions like vitiligo, atopic dermatitis, and alopecia areata, beyond their current psoriasis treatment.
STRATA's patents specifically cover the combination of UVB light therapy with systemic drugs, JAK inhibitors, and biological drugs, positioning the company at the forefront of integrative dermatologic treatment. The company is also engaged in defensive litigation with LaserOptek, expecting significant damages and injunctive relief.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.